Picture loading failed.

Anti-CD4 therapeutic antibody (Pre-made Ibalizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ibalizumab (trade name Trogarzo) is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a sub-class of HIV drugs called entry inhibitors.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-257-1mg 1mg 3090
GMP-Bios-ab-257-10mg 10mg 21890
GMP-Bios-ab-257-100mg 100mg 148000
GMP-Bios-ab-257-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD4 therapeutic antibody (Pre-made Ibalizumab biosimilar,Whole mAb)
INN Name Ibalizumab
TargetCD4
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI Structure3o2d:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
CompaniesBiogen Idec;TaiMed Biologics;Theratechnologies
Conditions ApprovedHIV-1 infections
Conditions Activena
Conditions Discontinuedna
Development Techna